News

Eveliqure Biotechnologies announced that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total…

Read more

It is long known that the acquired immune system can generate a vast antibody (immunoglobulin) repertoire by gene recombination in developing B-cells.…

Read more

The proposed function of the centriolar protein Cep97 has to be revised, a new study from the Dammerman lab shows. Rather than just limiting centriole…

Read more

Scientists from the Vienna BioCenter have pushed SARS-CoV-2 detection to a new level. Their approach is as sensitive and robust, yet cheaper, simpler…

Read more

Valneva SE and Bavarian Nordic A/S (OMX: BAVA) today announced that they have signed a binding term sheet to establish a partnership for the marketing…

Read more

Batavia Biosciences and Valneva Sweden AB, the Swedish subsidiary of Valneva SE announced that they have entered into a collaboration agreement to…

Read more

Valneva announced that the antitrust-related condition precedent for its Lyme vaccine collaboration agreement with Pfizer has been met. As a result,…

Read more

Researchers at IMBA and IMP develop a new CRISPR tool that predicts effective guide RNAs with unprecedented precision. They named it Vienna…

Read more

CEBINA announced that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale…

Read more

Eveliqure Biotechnologies has announced that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent…

Read more

Valneva announced the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed…

Read more

Researchers from the lab of Florian Raible at the Max Perutz Labs and their collaborators have developed an improved tissue clearing and…

Read more